← Leaderboards
Edward L Schwartz
Montefiore Medical Center (Bronx, Ny)
$6,745,000
Attributed
$8,146,003
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $837K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,146,003 · 6
By mechanism
R01$8,146,003 · 6
Top collaborators
- Hongling Zhao8 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsProteinsMouse ModelGrantInhibitor/AntagonistPharmaceutical PreparationsSolid NeoplasmMediatingMonocyteGeneticLeadNeoplasm MetastasisClinical TrialsGrowthCellsIntegrinsVascular Endothelial Growth FactorsApoptosisPathway InteractionsIn VitroAngiogenesisResponsePre-Clinical
Grant awards (29)
Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53$155,403
R01 · FY2024 · CA · contact PI
Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53$445,917
R01 · FY2023 · CA · contact PI
Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53$83,068
R01 · FY2022 · CA · contact PI
Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53$455,018
R01 · FY2021 · CA · contact PI
Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53$455,018
R01 · FY2020 · CA · contact PI
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis$382,013
R01 · FY2020 · CA · contact PI
Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53$455,018
R01 · FY2019 · CA · contact PI
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis$370,552
R01 · FY2019 · CA · contact PI
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis$346,525
R01 · FY2016 · CA · contact PI
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis$346,525
R01 · FY2015 · CA · contact PI
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis$336,129
R01 · FY2014 · CA · contact PI
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis$326,417
R01 · FY2013 · CA · contact PI
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis$364,002
R01 · FY2012 · CA · contact PI
Mechanisms of thymide phosphorylase angiogenesis$231,766
R01 · FY2010 · CA · contact PI
Mechanisms of thymide phosphorylase angiogenesis$229,616
R01 · FY2009 · CA · contact PI
Mechanisms of thymide phosphorylase angiogenesis$227,530
R01 · FY2008 · CA · contact PI
Anti-angiogenic actions of taxotere$240,915
R01 · FY2007 · CA · contact PI
Mechanisms of thymide phosphorylase angiogenesis$225,503
R01 · FY2007 · CA · contact PI
Anti-angiogenic actions of taxotere$248,111
R01 · FY2006 · CA · contact PI
Mechanisms of thymide phosphorylase angiogenesis$230,213
R01 · FY2006 · CA · contact PI
Anti-angiogenic actions of taxotere$254,082
R01 · FY2005 · CA
Anti-angiogenic actions of taxotere$254,082
R01 · FY2004 · CA
Mechanisms of thymidine phosphorylase angiogenesis$237,718
R01 · FY2004 · CA
Anti-angiogenic actions of taxotere$254,082
R01 · FY2003 · CA
Mechanisms of thymidine phosphorylase angiogenesis$237,718
R01 · FY2003 · CA
Mechanisms of thymidine phosphorylase angiogenesis$237,718
R01 · FY2002 · CA
Mechanisms of thymidine phosphorylase angiogenesis$237,718
R01 · FY2001 · CA
CELLULAR INTERACTIONS OF 5 FLUOROURACIL AND INTERFERON$214,089
R01 · FY2000 · CA
CELLULAR INTERACTIONS OF 5 FLUOROURACIL AND INTERFERON$63,537
R01 · FY2000 · CA